HCPCS G-Codes
Procedures/Professional Services (Temporary Codes)

Temporary G codes are assigned to services and procedures that are under review before being included in the CPT coding system. Payment for these services is under the jurisdiction of the local carriers.

• G8985

  Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting

• G8986

  Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting

• G8987

  Self care functional limitation, current status, at therapy episode outset and at reporting intervals

• G8988

  Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting

• G8989

  Self care functional limitation, discharge status, at discharge from therapy or to end reporting

• G8990

  Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals

• G8991

  Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting

• G8992

  Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting

• G8993

  Other physical or occupational therapy subsequent functional limitation, current status, at therapy episode outset and at reporting intervals

• G8994

  Other physical or occupational therapy subsequent functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting

• ---

  ---

  Continued

• G8995

  Other physical or occupational therapy subsequent functional limitation, discharge status, at discharge from therapy or to end reporting

• G8996

  Swallowing functional limitation, current status at therapy episode outset and at reporting intervals

• G8997

  Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting

• G8998

  Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting

• G8999

  Motor speech functional limitation, current status at therapy episode outset and at reporting intervals

• G9001

  Coordinated care fee, initial rate

• G9002

  Coordinated care fee, maintenance rate

• G9003

  Coordinated care fee, risk adjusted high, initial

• G9004

  Coordinated care fee, risk adjusted low, initial

• G9005

  Coordinated care fee, risk adjusted maintenance

• G9006

  Coordinated care fee, home monitoring

• G9007

  Coordinated care fee, scheduled team conference

• G9008

  Coordinated care fee, physician coordinated care oversight services

• G9009

  Coordinated care fee, risk adjusted maintenance, level 3

• G9010

  Coordinated care fee, risk adjusted maintenance, level 4

• G9011

  Coordinated care fee, risk adjusted maintenance, level 5

• G9012

  Other specified case management service not elsewhere classified

• G9013

  Esrd demo basic bundle level i

• G9014

  Esrd demo expanded bundle including venous access and related services

• G9016

  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]

• ---

  ---

  Continued

• G9017

  Amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)

• G9018

  Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)

• G9019

  Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)

• G9020

  Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)

• G9033

  Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)

• G9034

  Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)

• G9035

  Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)

• G9036

  Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)

• G9037

  Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional for the care of the patient (i.e. not for professional education or scheduling) and may include subsequent follow up on the specialist's recommendations; 30 minutes

• G9038

  Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for which specialist is taking a co-management role; condition expected to last at least 3 months; comprehensive care plan established, implemented, revised or monitored in partnership with co-managing clinicians; ongoing communication and care coordination between co-managing clinicians furnishing care

• G9050

  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)

• G9051

  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a medicare-approved demonstration project)

• G9052

  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)

• G9053

  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)

• G9054

  Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies (for use in a medicare-approved demonstration project)

• G9055

  Oncology; primary focus of visit; other, unspecified service not otherwise listed (for use in a medicare-approved demonstration project)

• G9056

  Oncology; practice guidelines; management adheres to guidelines (for use in a medicare-approved demonstration project)

• G9057

  Oncology; practice guidelines; management differs from guidelines as a result of patient enrollment in an institutional review board approved clinical trial (for use in a medicare-approved demonstration project)

• G9058

  Oncology; practice guidelines; management differs from guidelines because the treating physician disagrees with guideline recommendations (for use in a medicare-approved demonstration project)

• G9059

  Oncology; practice guidelines; management differs from guidelines because the patient, after being offered treatment consistent with guidelines, has opted for alternative treatment or management, including no treatment (for use in a medicare-approved demonstration project)